<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00491569</url>
  </required_header>
  <id_info>
    <org_study_id>NSC-94-2314-B-039-026</org_study_id>
    <nct_id>NCT00491569</nct_id>
  </id_info>
  <brief_title>Sarcosine or D-Serine Add-on Treatment for Chronic Schizophrenia</brief_title>
  <official_title>NMDA Enhancers in the Treatment of Schizophrenia: Sarcosine vs. D-Serine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China Medical University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Science Council, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Health Research Institutes, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>China Medical University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Both GlyT-1 inhibitors and NMDA-glycine site agonists have been demonstrated to be beneficial&#xD;
      for chronic schizophrenia patients.&#xD;
&#xD;
      The purpose of this study is to compare efficacy and safety of add-on treatment of sarcosine,&#xD;
      a GlyT-1 inhibitor, and D-serine, an NMDA-glycine site agonist, in chronically stable&#xD;
      schizophrenia patients who have been stabilized with antipsychotics.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The etiology of schizophrenia remains unclear. Schizophrenia patients reveal positive&#xD;
      symptoms, negative symptoms, and cognitive impairments. In addition to dopamine system&#xD;
      hyperactivity, hypofunction of N-methyl-D-aspartate (NMDA) receptor plays a role in the&#xD;
      pathophysiology of schizophrenia. Consequently, enhancing NMDA receptor neurotransmission has&#xD;
      been regarded as a novel treatment approach. To date, there have been several reported trials&#xD;
      on NMDA enhancers. Both sarcosine (N-methylglycine, a glycine transporter I inhibitor) and&#xD;
      D-serine (a potent NMDA-glycine site agonist) showed therapeutic effects in chronically&#xD;
      stable patients. Interestingly, sarcosine appeared more efficacious than D-serine in acutely&#xD;
      exacerbated ones when added-on to antipsychotics. Both sarcosine and D-serine yielded&#xD;
      excellent safety profiles.&#xD;
&#xD;
      It remains unclear whether sarcosine can be also more efficacious than D-serine in the&#xD;
      treatment for chronically stable schizophrenia. The aim of this project is to examine the&#xD;
      efficacy and safety of add-on treatment of sarcosine vs. D-serine in chronically stable&#xD;
      schizophrenia patients who have been stabilized with antipsychotics.&#xD;
&#xD;
      In the study, 60-75 schizophrenic patients are recruited into the 6-week trial and randomly&#xD;
      assigned into the three groups (2 gm/d sarcosine, 2 gm/d D-serine, or placebo) with a&#xD;
      double-blind manner. Clinical manifestation (Positive and Negative Syndrome Scale [PANSS],&#xD;
      side effects and quality of life (QOL) are evaluated every two weeks during the trial.. The&#xD;
      efficacies of three groups are compared.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total scores of Positive and Negative Syndrome Scale (PANSS) and Quality of Life (QOL)</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subscales of PANSS</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">60</enrollment>
  <condition>Schizophrenias</condition>
  <condition>Psychoses</condition>
  <condition>Psychotic Disorders</condition>
  <condition>Schizophrenic Disorders</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sarcosine and D-serine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Fulfill the criteria of schizophrenia according to the Diagnostic and Statistic&#xD;
             Manual, fourth edition (DSM-IV).&#xD;
&#xD;
          -  Agree to participate in the study and provide informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Meet DSM-IV criteria of major mood disorder, current substance dependence or mental&#xD;
             retardation&#xD;
&#xD;
          -  History of epilepsy, head trauma or CNS diseases&#xD;
&#xD;
          -  Major, untreated medical diseases&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hsien-Yuan Lane, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Psychiatry, China Medical University Hospital, Taiwan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>404</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Lane HY, Chang YC, Liu YC, Chiu CC, Tsai GE. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. Arch Gen Psychiatry. 2005 Nov;62(11):1196-204. doi: 10.1001/archpsyc.62.11.1196.</citation>
    <PMID>16275807</PMID>
  </reference>
  <verification_date>June 2007</verification_date>
  <study_first_submitted>June 24, 2007</study_first_submitted>
  <study_first_submitted_qc>June 24, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2007</study_first_posted>
  <last_update_submitted>June 24, 2007</last_update_submitted>
  <last_update_submitted_qc>June 24, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2007</last_update_posted>
  <keyword>Schizophrenia</keyword>
  <keyword>sarcosine</keyword>
  <keyword>D-serine</keyword>
  <keyword>NMDA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

